Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.
about
Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factorsBarriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a reviewCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersEligibility of persons who inject drugs for treatment of hepatitis C virus infection.Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.Hepatitis C management by addiction medicine physicians: results from a national surveyPhysicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug usersHepatitis infection in the treatment of opioid dependence and abuse.Molecular and contextual markers of hepatitis C virus and drug abuse.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users.Managing Hepatitis C in Users of Illicit DrugsManagement of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapyTreatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centreCritical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.Publicly funded pegylated interferon-alpha treatment in British Columbia: disparities in treatment patterns for people with hepatitis CSuccessful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.Current approaches to HCV infection in current and former injection drug users.Limited uptake of hepatitis C treatment among injection drug usersInterferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.Methadone: a review of drug-drug and pathophysiological interactions.Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users.The role of hepatology nurse in the difficult-to-treat hepatitis C population.Injection drug users: the overlooked core of the hepatitis C epidemic.Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation.Hepatitis C infection and injection drug use: the role of hepatologists in evolving treatment efforts.
P2860
Q26853671-B263EC7E-0E6B-4F7E-ADE8-4D9555271120Q27010548-B17A164D-F1AD-4773-A256-E2F4FB3AFCCFQ28483820-60CB8FA5-44F9-44B5-8228-88FE250C6298Q30429470-93ADA539-81C8-41A0-A128-1870204B57CEQ33858467-053D6F00-E1EA-4367-A67B-D563AD294E1CQ34090853-A9DB8992-3E17-4245-B305-158733A16730Q34789013-D99C7F6C-070C-4422-95F5-D12FE0813EA0Q34795051-D5D48707-06BD-4BA7-A9A5-0E7BAEE39E5DQ34795057-5F10D914-835A-4E85-9433-1919612EAB7EQ35389163-0DFC326C-7685-484B-8595-10B2A9C23C0CQ35660841-1C560FFF-8EF7-426E-ABB4-ABC5DB37BF0FQ36079786-ECA69A9E-6E97-4651-8681-9CBC9AB0D4DBQ36376962-D62285D2-8636-4E77-BE16-AC4F99044DD5Q36535234-27241D80-B574-40A0-8BBA-D3A3671BBC92Q36948673-22BD500C-41A4-40F5-A559-B2A70BF2B490Q37042436-F703F66D-02E1-4D83-A2D0-F728D1874EE6Q37092648-9B6A30C6-97C2-4257-976D-69D762E8B23EQ37142229-165D1355-2796-4FDA-BEBD-FC0162BAD30CQ37144240-F5789522-ED34-4E79-BE0B-4D58B1BAA194Q37216987-33B52B9D-9894-404E-9DF8-D325B27A9AA4Q37235530-0D5AA7D2-CF0A-486A-85D5-1B2393E47780Q37238205-1CF4AEC4-2BAE-411B-AA07-B58C3570AA93Q37432112-F4D2A13F-F64A-485F-9174-CF683277E449Q37950478-DAAAF1B2-580B-46B4-BE0B-621D59C0F898Q39918668-920DEB27-59A6-4219-BDEE-8FB54507DD38Q41047662-9CA3FD3A-712C-441B-8C4E-68094B2D2934Q41930106-ADBA118A-FBD5-4DA4-A9F8-8DE1DF0F883DQ42280296-37311513-932F-4AF2-A70B-798B58C2C24EQ42510746-75946342-D752-490E-B939-C88C56197143Q42685176-202E2337-20C5-489B-92B6-0A056038EBFFQ43039432-A7771CA0-B065-409D-8D5F-B4AAACBFF653Q43159898-56B57D9A-3812-47DC-A4B7-7CD2C86F4159Q43234059-B19229FD-B91C-4E9C-8C19-0BBF013E88B7Q44330573-504E18A9-CF2E-4643-90CE-CFF30DED8D2DQ52286501-FE7ACB02-3C25-490D-A61F-84CCBA0C7EB5
P2860
Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Response to treatment of hepat ...... ory of intravenous drug abuse.
@en
Response to treatment of hepat ...... ory of intravenous drug abuse.
@nl
type
label
Response to treatment of hepat ...... ory of intravenous drug abuse.
@en
Response to treatment of hepat ...... ory of intravenous drug abuse.
@nl
prefLabel
Response to treatment of hepat ...... ory of intravenous drug abuse.
@en
Response to treatment of hepat ...... ory of intravenous drug abuse.
@nl
P2093
P1476
Response to treatment of hepat ...... ory of intravenous drug abuse.
@en
P2093
Abhinandana Anantharaju
David H Van Thiel
Steven Creech
P304
P356
10.1016/S0002-9270(03)00708-1
P407
P577
2003-10-01T00:00:00Z